stockrow
Saturday 7 November 2026
Export BSEM’s income statement to Excel — free account
BioStem Technologies, Inc.
BSEM Healthcare Biotechnology
- Revenue
- −28.0%
- EPS
- −86,766.7%
Quarter to June 2026, against a year earlier
1.13
0.09
+8.65%
Follow BSEM
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 17 | 302 | 47 | 35 | +68.7% | 29 | 54 | 85 | +21.3% | |
| Gross margin, % | — | — | — | — | — | — | — | 100.00 | 100.00 | 100.00 | 91.16 | 0.0 pt | ||||||
| EBT | — | — | — | — | — | — | — | 17 | 302 | 47 | 18 | +68.7% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | 100.00 | 100.00 | 100.00 | 51.22 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | — | — | (13) | — | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 1.22 | 18.44 | 2.84 | 2.00 | +52.7% | |||||
| Earnings | — | — | — | — | — | — | — | (0.57) | 1.95 | (0.39) | (1.54) | (17.3%) | ||||||
| Cash flow | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Capex | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Book value | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 1.59 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | 14 | 16 | 17 | 17 | +10.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 15.45 | 6.85 | 0.00 | 0.00 | 7.4 | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.75 | 0.61 | 0.56 | 0.5 | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.00 | 1.63 | 0.70 | 0.5 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.75 | 0.33 | 0.36 | 0.4 | ||||||
| EV/FCF | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| Net debt | — | — | — | — | — | — | — | — | — | — | (7) | — | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | — | — | 28 | — | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | |||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 55.34 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 2 Nov 2026
BioStem Technologies, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MCRB Seres Therapeutics, Inc. | $20.8M | — (loss-making) | — (loss-making) | +68.95% (above 0%: growing) | n/m | −576.66% (below 0%: shrinking) | 100.00% | (2,723.78%) | Compare |
| ATOS Atossa Therapeutics, Inc. | $20.2M | — (loss-making) | — | −94.28% (below 0%: shrinking) | n/m | −32.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IMMP Prima BioMed Ltd | $19.8M | — | — | — | n/m | −589,653.13% (below 0%: shrinking) | 100.00% | (101.89%) | Compare |
| BSEM BioStem Technologies, Inc. | $19.4M | — (loss-making) | — (loss-making) | −27.95% (below 0%: shrinking) | n/m | — | 61.28% | (106.35%) | |
| COCP Cocrystal Pharma, Inc. | $19.3M | — (loss-making) | — (loss-making) | −81.05% (below 0%: shrinking) | n/m | −16.75% (below 0%: shrinking) | 100.00% | (3,032.38%) | Compare |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR | $18.5M | — (loss-making) | — | — | n/m | −510.28% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ACTU Actuate Therapeutics, Inc. | $18.0M | — (loss-making) | — | — | n/m | −5.54% (below 0%: shrinking) | — | 0.00% | Compare |
| ESLA Estrella Immunopharma, Inc. | $17.8M | — (loss-making) | — | — | n/m | −329.19% (below 0%: shrinking) | — | 0.00% | Compare |
| KTTA Pasithea Therapeutics Corp. | $17.4M | — (loss-making) | — (loss-making) | +1,494.04% (above 0%: growing) | n/m | −21.68% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $18.9M | — | — | −6.05% | — | −181.02% | 50.00% | 0.00% |